Austco Healthcare Limited (ASX:AHC)

Austco Healthcare Limited’s FY26 results media release reports record revenue of A$94.2 million, up 16% on FY25, with growth supported by organic expansion and a full-year contribution from the G&S acquisition, while software and software maintenance agreement revenue rose 19% to A$11.4 million and gross margin improved to 53.4% from 52.0%; EBITDA increased 14% to A$14.9 million, net profit before tax rose 44% to A$11.6 million, and NPAT increased 52% to A$9.0 million, aided by a lower effective tax rate and a favourable revision to G&S contingent consideration, although overheads rose to A$39.9 million due largely to acquisitions and softer second-half revenue timing; the company reported unfilled contracted revenue of A$51.2 million as at 17 August 2026, up 13% from 30 June 2026, with most of the order book denominated in foreign currencies, invested A$4.8 million in R&D including A$2.0 million capitalised for Tacera, ended FY26 with A$16.3 million cash and A$12.5 million operating cash flow, declared no dividend in order to prioritise organic and inorganic growth, and said it enters FY27 with confidence supported by its order book, recurring software base, integrated reseller acquisitions, and favourable long-term healthcare demand drivers.